Bioscience

TGen affiliate, VARI, joins with Spectrum Health and oncology group to develop Phase I clinical trial program

July 27, 2010

By Flinn Foundation

[Source: TGen] – An affiliate of the Translational Genomics Research Institute (TGen) will provide cancer patients in West Michigan opportunities to access new drugs to fight their disease, according to an agreement announced today.

Van Andel Research Institute (VARI), an affiliate of TGen, is joining with Spectrum Health and Cancer & Hematology Centers of Western Michigan to develop a Phase I clinical trial program.

The program will be the link between the lab and clinical research involving patients, allowing faster, close-to-home enhanced access to potentially life-saving diagnostic and treatment options for cancer and other clinical conditions.

For more information: TGen affiliate, Van Andel Research Institute, joins with Spectrum Health and oncology group to develop Phase I clinical trial program